MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ
0.6723
+0.0023
+0.34%
After Hours: 0.6600 -0.0123 -1.83% 17:00 01/27 EST
OPEN
0.7000
PREV CLOSE
0.6700
HIGH
0.7000
LOW
0.6450
VOLUME
35.03K
TURNOVER
0
52 WEEK HIGH
6.00
52 WEEK LOW
0.5005
MARKET CAP
28.93M
P/E (TTM)
-1.0157
1D
5D
1M
3M
1Y
5Y
BRIEF-Sab Biotherapeutics Inc Received Nasdaq Notice Of Delisting
Reuters · 2d ago
BRIEF-SAB Biotherapeutics Receives $8.2 Million In Closeout Of DoD Contract
Reuters · 01/18 17:50
SAB Biotherapeutics (SABS) Receives a Buy from H.C. Wainwright
TipRanks · 01/18 15:45
SAB Biotherapeutics gets additional $8.2M in funding in closeout DoD contract
Seeking Alpha · 01/18 13:38
EXCLUSIVE: SAB Biotherapeutics Receives Additional $8.2M In Closeout Of COVID-19 DoD Contract
Benzinga · 01/18 12:31
SAB Biotherapeutics Receives Additional $8.2 Million From US Defense Department in Closeout of Contract
SAB Biotherapeutics Receives Additional $8.2 Million From US Defense Department in Closeout of Contract
MT Newswires · 01/18 09:32
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 01/11 21:31
H.C. Wainwright Remains a Buy on SAB Biotherapeutics (SABS)
TipRanks · 01/10 14:55
More
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases and immune and autoimmune disorders. The Company uses its immunotherapy platform, DiversitAb, to produce a new class of specifically targeted, fully human polyclonal antibodies without the need for human donors and applies to a range of serious unmet needs in human diseases. The Company's product candidates include SAB-185, which is a fully human polyclonal antibody therapeutic for the treatment of Coronavirus disease (COVID-19), and SAB-176, a multivalent, neutralizing fully human polyclonal antibody therapeutic candidate designed to bind to Type A and B influenza viruses. The Company's pre-clinical product candidates are in development for autoimmune diseases, including SAB-142 for Type 1 Diabetes and organ transplant induction and early discovery work in oncology.

Webull offers kinds of SAB Biotherapeutics Inc stock information, including NASDAQ:SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.